Saltar al contenido
Merck

C-909

Supelco

Clobazam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C16H13ClN2O2
Número de CAS:
Peso molecular:
300.74
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

CN1C(=O)CC(=O)N(c2ccccc2)c3cc(Cl)ccc13

InChI

1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3

InChI key

CXOXHMZGEKVPMT-UHFFFAOYSA-N

General description

A Certified Spiking Solution® suitable for use as starting material in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing. Clobazam, marketed under trade names Frisium, Urbanol, and Onfi® is benzodiazapene drug prescribed to treat anxiety and epilepsy.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Onfi is a registered trademark of Lundbeck LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Mark Naccarato et al.
Antiviral therapy, 17(3), 589-592 (2012-02-02)
The cytochrome P450 isoforms primarily involved in clobazam metabolism are CYP3A4 and 2C19. Drugs that modulate these enzymes would then be expected to alter the exposure of clobazam and its major metabolites. Etravirine, a second-generation non-nucleoside reverse transcriptase inhibitor has
Lily P H Yang et al.
CNS drugs, 26(11), 983-991 (2012-10-05)
Clobazam, as with other benzodiazepines, has a long history of use in the treatment of epilepsy. More recently, it was approved in the USA as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome in patients aged ≥2 years.
R Galimi
Minerva pediatrica, 64(3), 347-355 (2012-05-05)
The diagnosis and management of nonconvulsive status epilepticus (NCSE) pose special challenges in childhood. NCSE can be defined as a condition of ongoing or intermittent clinical epileptic activity without convulsions, for at least 30 minutes, with electroencephalographic evidence of seizures.
R T Owen
Drugs of today (Barcelona, Spain : 1998), 48(11), 697-703 (2012-11-22)
Clobazam, a 1,5-benzodiazepine, has been available in many European countries since the 1970s, both as an anxiolytic and as an antiepileptic. Recently, it has been marketed in the U.S. for the adjunctive treatment of Lennox-Gastaut syndrome, a seizure disorder accompanied
Yu-Tze Ng et al.
Epilepsy & behavior : E&B, 25(4), 687-694 (2012-11-13)
In an ongoing open-label extension (OV-1004), patients with Lennox-Gastaut syndrome who had completed 1 of 2 randomized controlled trials (OV-1002 [Phase II] or OV-1012 [Phase III]) are receiving clobazam at dosages ≤2.0 mg/kg/day (≤80 mg/day). Of 306 eligible patients from

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico